ONVO - חוב כולל להון Organovo Corp

Organovo Holdings, Inc. (ONVO) management relies on a serious scientific background, yet their preclinical experience has not yet translated into profit. The business's speculative potential is based on patents for living tissue printing, the demand for which is limited to a small number of pharma behemoths. This chart of the current share price demonstrates a debt-to-equity ratio of 3.39, while the team develops 3D liver models for organ therapy.

As a 3D bioprinting pioneer with colossal R&D expenditures, Organovo Holdings, Inc. requires precise control over borrowed funds to sustain its scientific activities. By analyzing the company's debt-to-equity ratio, an investor assesses the degree of leverage by comparing total liabilities with equity, where a rising curve signals increased bankruptcy risks in the event of declining market demand.